Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

The Pharma Data

APRIL 6, 2022

. “With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid- and long-term.” ” Integrating Pharmaceuticals and Oncology business units.

International 52

International Pharmaceuticals Drug Development Compliance 52

Agency IQ

AUGUST 2, 2024

While this would not affect existing vouchers, it would prevent FDA from issuing new ones after September 2026. FDA September 30 Deadline for submission of Advancing RWE Pilot Program projects A semi-annual deadline for FDA’s Advancing Real-World Evidence Program is set for the end of the fiscal year.

FDA 40

FDA Science Regulations Biosimilars 40

The Pharma Data

DECEMBER 8, 2020

8, 2020 /PRNewswire/ — At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. Ionis also has plans to expand opportunistically to new products in additional treatment areas such as hematology, endocrinology and pulmonology. . Potential to launch 6+ new products in next five years. CARLSBAD, Calif. ,

RNA 52

RNA Pharmaceuticals Production Disease 52

Drug Discovery World

JANUARY 24, 2024

Phase I of the clinical program will dose healthy volunteers with single ascending doses of FIB992 before proceeding to a multiple ascending dose study where the drug is administered for a two-week period. MT: What technologies are Fibrocor Therapeutics utilising to advance its drug development process?

Small Molecule 147

Small Molecule Research Pharma Companies Disease 147

Drug Discovery World

FEBRUARY 26, 2024

Reece Armstrong speaks to Kathryn Golden , SVP Technical Operations and Manufacturing, bit.bio, about novel technologies, and methods to manufacture human cells for therapies so more patients can access these treatments. Cell therapies have emerged as transformative and potentially curative treatments across a range of disease areas.

Therapies 130

Therapies Treatment Engineering Disease 130

Drug Discovery World

NOVEMBER 14, 2022

billion by 2026, at a compound annual growth rate (CAGR) of 28.4% during the forecast period of 2021-2026. Just taking a small snapshot of the current sector shines a light on the depth of development taking place. With reports of the drug being prescribed to President Biden, the drug recently hit the headlines. .

DNA 130

DNA Drugs Engineering Production 130